In this segment, Ms. Haupert shares the key questions and concerns she had when discussing treatment options for advanced ...

For the second time, the U.S. Food and Drug Administration has refused to approve Replimune Group’s experimental skin cancer ...

In this segment, Ms. Haupert shares her personal experience navigating advanced melanoma, offering valuable insight into the ...

Replimune (REPL) stock crashed 19% after FDA rejected RP1 melanoma treatment for second time, citing trial design issues.

Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial ...

The MedStar Georgetown University Hospital began implementing a new treatment for metastatic melanoma that fights a patient’s cancer using their own immune system and cancerous cells, the hospital ...

A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.

Teddi Mellencamp has shared a sobering update on her health. On April 2, The Real Housewives of Beverly Hills alum said in an emotional Instagram video that she now has stage IV cancer. Mellencamp was ...

Melanoma is a deadly form of skin cancer that is typically removed surgically. Now, researchers publishing in ACS Nano report ...

Shares of biotech Replimune Group sank more than 19% after the Food and Drug Administration rejected an application seeking ...

Replimune Group Inc. shares plunged after US regulators rejected the company’s skin cancer treatment for a second time, a sign that they are maintaining their tough stance on drug reviews.